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Abstract
Purpose – Patient safety is gaining prominence in health professional curricula. Patient safety must be
complemented by teaching and skill development in practice settings. The purpose of this paper is to explore
how experienced pharmacists identify, prioritize and communicate adverse drug effects to patients.
Design/methodology/approach – A focus group discussion was conducted with cardiology pharmacy
specialists working in a Doha hospital, Qatar. The topic guide sought to explore participants’ views,
experiences and approaches to educating patients regarding specific cardiovascular therapy safety and
tolerability. Discussions were audio-recorded and transcribed verbatim. Data were coded and organized
around identified themes and sub-themes. Working theories were developed by the three authors based on
relevant topic characteristics associated with the means in which pharmacists prioritize and choose adverse
effect information to communicate to patients.
Findings – Nine pharmacists participated in the discussion. The specific adverse effects prioritized were
consistent with the reported highest prevalence. Concepts and connections to three main themes described how
pharmacists further tailored patient counseling: potential adverse effects and their perceived importance; patient
encounter; and cultural factors. Pharmacists relied on initial patient dialogue to judge an individual’s needs and
capabilities to digest safety information, and drew heavily upon experience with other counseling encounters to
further prioritize this information, processes dependent upon development and accessing exemplar cases.
Originality/value – The findings underscore practical experience as a critical instructional element of
undergraduate health professional patient safety curricula and for developing associated clinical reasoning.
Keywords Patient safety, Education, Medicine
Paper type Research paper
Introduction
The importance of structured practical experience (clinical internship) in the health
professional curriculum, to consolidate, reinforce and advance knowledge and skills, cannot
be understated as a critical quality learning determinant and a subsequent comfort as a
practicing clinician (Miettinen, 2000; Kolb, 2014). Indeed, it is within authentic care settings,
under clinical supervisor guidance, that students participate in patient care experiences to
develop and ultimately achieve the professional competencies necessary to work safely and
independently (Kogan et al., 2014). Such supervised experiential training assumes
importance beyond educational interests and notably includes public health benefits.
Medical error is recognized as a leading contributor to healthcare-related morbidity and
mortality worldwide, prompting patient safety concepts and practices to become
increasingly explicit in health professional education (Makary and Daniel, 2016). In 2011,
the World Health Organization (2011) released a multi-professional patient safety
curriculum, which recommended specific patient safety principles in course content. Given
that medication misadventure, including prescribing errors and adverse drug events,
accounts for a sizable proportion of overall medical errors and is often preventable.
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Unsurprisingly, medication safety principles are, therefore, highlighted in the education
of disciplines participating in the drug use process (Frank, 2005; American Association of
Colleges of Nursing, 2006). Pharmacy students are trained to ensure drug therapy accuracy
and quality and to evaluate medication and patient safety during treatment (Association of
Faculties of Pharmacy of Canada, 2010).
When a patient is prescribed or self-selects over-the-counter drug therapy, one
pharmacist responsibility is to provide medication counseling, which includes education on
how the patient might identify and subsequently manage adverse events. Preventable
drug-related emergency department visits and hospital admission have been attributed to
inappropriate drug monitoring or failure to evaluate predictable medication side effects,
underscoring the need for such dialogue (Beijer and de Blaey, 2002; Forster et al., 2003;
Howard et al., 2006). Research demonstrates the high value various patient populations
place on such information (Astrom et al., 2000; Nair et al., 2002; Berry et al., 1997; Al Amri,
2009; Piredda et al., 2008; Al-Saffar et al., 2008). However, knowledge gaps persist in studies
exploring communicated and retained patient information, up to 60 percent were unaware of
safety information associated with their prescribed drugs (Tarn, et al., 2006; Erikson, 2016).
To develop professional competency, pharmacy students must first identify what possible
adverse effects are ascribed to drug therapy. This information is readily available from
curricular and external resources. Unfortunately, for various medico-legal and academic
reasons, the possible adverse effects that may be recorded for any given drug are numerous
and include rare, unusual and unlikely reactions. While patients have the right to learn drug
therapy risks, it is essential for pharmacists to offer this information within a clinically relevant
framework to avoid alarming the patient unnecessarily or unintentionally and introducing
discordance with what information the prescriber has previously offered ( Jones et al., 2006;
Taylor, 2011). Additionally, pharmacists often have little time to offer medication and health
counseling during the patient visit. Pharmacy students must then learn to offer accurate and
relevant patient-specific education regarding medication risks in an efficient manner. It is still
unclear how novice practitioners do so and how undergraduate pharmacy training can
improve these processes. Deciding how to effectively teach clinical skills associated with risk
communication have been less well explored when compared to diagnostic reasoning and
decision-making studies among physicians and medical trainees (Boshuizen and Schmidt,
1992; Norman, 2005; Schmidt and Rikers, 2007; Durning et al., 2013; Bowen, 2006).
Little pedagogy extends to the important clinical pharmacy skill: communicating clinically
relevant adverse drug effect information to patients. Our objective, therefore, is to: explore
how experienced pharmacists identify, prioritize and communicate adverse drug effect
information to their patients; and inform pharmacy student training in this regard.
Methods
A qualitative design employing focus group and semi-structured discussion were used for
data collection. In total, 17 pharmacists working in the Heart Hospital, the only specialty
cardiology referral center in Qatar, were invited to participate. Previous studies found that
approximately 10 percent of patients experience a medication-related adverse event within
one month following hospital discharge (Forster et al., 2003). As cardiovascular therapies
represent one main drug class implicated in medication-related adverse events, we targeted
our inquiry on care providers for this drugs group (Howard et al., 2006). A topic guide was
developed following a comprehensive literature review of other quantitative or qualitative
assessments that reported side effect counseling or risk communication strategies.
Our framework explored consenting participants’ views, experiences and approaches to
educating patients regarding treatment safety and tolerability. Selected medications were
associated with hypertension, heart failure and myocardial infarction management:
hydrochlorothiazide (diuretic); ramipril (angiotensin converting enzyme inhibitor);
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atenolol (beta blocker); ASA and copylores (antiplatelets). After each discussion,
participants were given the opportunity to ask additional questions or make further
contributions. The audio-taped focus group and semi-structured interviews were conducted
and transcribed by the primary investigator and subsequently verified independently by
two research assistants.
Qualitative data analysis was supported by NVivo10© software. Transcripts were read
several times by primary investigators to sense the whole and then subjected to latent
content analysis. The text was divided into related words, sentences or paragraphs through
their content and context as units of meaning. Data were then coded and organized around
identified themes and sub-themes based on their similarities and differences. Working
theories were drawn by the three primary investigators based on relevant topic
characteristics associated with how pharmacists prioritize and choose adverse effect
information for communication to patients. Additionally, cardiovascular drug adverse
events were documented from electronic tertiary and associated primary resources
(Lexicomp© and Micromedex©) for comparison with those side effects and intolerances
selected by our participants (Crommelinck and Anseel, 2013; Pelgrim et al., 2013).
Ethical approval was obtained from Qatar University Institutional Review Board.
Results
Nine consenting pharmacists joined the focus group discussion. The other eight were unavailable
for a second focus group or did not consent. Specialization in cardiology care averaged six years
(sod¼ 2.1). Over 50 intolerances and toxicities are listed in medication product monographs
chosen for review; however, the cardiovascular therapy-specific adverse effects prioritized by the
participants were mostly consistent with reported highest prevalence (Table I).
Concepts and connections to three main themes were determined, describing how
pharmacists tailored patient counseling on potential adverse effects and their perceived
importance; encounter; and cultural factors.
Adverse effects
As indicated, pharmacists prioritized the specific adverse effects they communicated to
patients using event prevalence for the drug/s in question. Those with additional
perceived importance often accompanied these common adverse effects, namely, ones
Drug therapy Pharmacist prioritization Prevalence (%)a
Thiazide-like diuretic: hydrochlorothiazide Hypokalemia 15-50
Hyperglycemia 1-5
Hyperuricemia 1-3
ACE inhibitor: ramipril Hyperkalemia 1-10
Dry cough 8-12
Hypotension 11
Renal artery stenosis 1
Beta blocker: atenolol Fatigue 1-10
Hypotension 1-27
Bradycardia 1-16
Antiplatelet Minor bleeding 3-5.6
Pruritis (cladogram) 2-4
Allergy 4-23
Gastric upset (aspirin) 6-31
Sources: aLexicomp Online Database (2016), Lexicomp Inc. (http://online.lexi.com/, accessed July 20, 2016);
Micromedex Drugdex (2016), Truven Health Analytics (www.micromedexsolutions.com/, accessed July 20, 2016)
Table I.
Adverse effects
identified by
pharmacists
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with life-threatening consequences. The important serious reactions were informed
by written resources, influenced heavily by professional experience, e.g., two pharmacists
were familiar with hemorrhagic retinopathy occurring during antiplatelet treatment and
are now particular about including vision changes that patient’s may detect (a bleeding
side effect). Others described how nearly every beta blocker user was reporting fatigue
and so they purposefully prepare their patients on what to expect, even before counseling
related to low blood pressure or heart rate. Concurrent drug therapy and known
concomitant disease states were also invoked as meaningful elements to individualize
patient counseling, e.g., highlighting possible shortness of breath in individuals with
asthma and prescribed ASA. When asked about their approach to establishing
newly marketed medication adverse effects, pharmacists cited electronic monographs
(e.g. Lexicomp© or Micromedex©) for the usual ones and primary literature resources and
government (USA, Europe) health agency safety alerts for those previously
underestimated or unanticipated.
Patient encounter
Significant consideration for patient factors further directed patient education. In addition to
confirming or gathering additional information regarding the patient’s medical condition
and other medications in the clinical encounter, pharmacists also try to discern other
pertinent aspects, such as education level or attitudes toward treatment. They rely on this
initial dialogue to judge the individual’s needs and capabilities to digest safety information:
I think first thing for the side effects, you will assess the patient psychologically. So, once you know
his condition and once you know how he will accept the information, you will go further or you will
stop, you will speak in general speech or you will speak in detail. Sometimes the patients [persist in
asking what [are] the side effects? [In these cases] you will go further and tell him [all side effects]
even if it’s low percentage.
You should evaluate every person. If he is frustrated […] and he seems not compliant and he is not
willing to take the medication, try to avoid that in the end [too much side effect information]. At the
same time, because it is your responsibility to state the side effects, just tell them if you find
anything that is not like something that is not normal come back to us, talk to us.
Patient encounter length and timing also dictated how side effects were communicated.
Outpatient pharmacists described the constraints (practice and patient based) on counseling
time owing to volume and occasionally, an individual’s impatience when collecting
prescriptions. Conversely, it was acknowledged that this setting could facilitate an
ultimately complete and thorough medication education across further follow-up encounters
for care and or repeat visits for prescription renewal.
Cultural factors
Pharmacists understood the social context in which they provide healthcare, weighing
professional responsibilities, to give patients precautionary information faced with the
populations’ anticipated responses and behaviors:
Shall we speak with the patient frankly and tell him all the side effects expected or do we minimize
the side effects, which we can tell the patient? This is the question. We have a different
categorization of patients here, especially Qatari or especially Gulf people, we have a good
experience with that. If I tell him every side effect, I know about the medication, we have a problem.
If you tell a patient about this [side effects], he might not take the medication because he worries
about the side effects, especially in our culture.
Participants pointed out that they must often overcome language barriers when offering
even basic directions for safe medication administration. Even when pharmacist and patient
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share a first language, low literacy levels also posed problems in achieving a dialogue
beyond dosing instructions:
[Most] patients, they are not speaking English [or Arabic] by the way. We had a study […] and
[most] patients, almost 75%, they are from South Asia so this is one of the [biggest] obstacles for us.
So sometimes you have this hard time […] due to the language barrier or due to [poor] literacy also
because they are not that educated.
When asked at the focus group’s conclusion for any advice when teaching students about
communicating clinically relevant side effects, pharmacists described tactics consistent with
some current instructional methods. Adverse effect information is ideally not offered in
isolation, but coupled with the potential management strategies and expected responses:
[For ACE inhibitor] If you experience dry cough, then you might want to change the medication,
and I always relate the solution to the problem.
[For BB] it is ok to try to decrease exercise in the first week because you may not feel as able as
before, but after one week or two weeks you might be able to tolerate [activity].
While our research question and topic guide focused on medication counseling from a safety
perspective, pharmacists also stressed that it is drug therapy benefits that are best
emphasized during the patient encounter. Finally, they cautioned against a rigid approach
to teaching students, instead outlining general processes to maintain flexibility according to
each situation.
Research implications and limitations
We found that expert cardiology pharmacists used widely accessible resources when
choosing the most commonly reported adverse effects to communicate during medication
counseling, but drew heavily upon other professional judgments to further prioritize this
information. Patient experiences reinforced the desire to communicate safety information
acquired through other objective means, including high prevalent adverse effects
(e.g. gastro-intestinal bleeding and bruising) and some unorthodox ones (e.g. retinal
hemorrhage). Some clinicians and educators might dispute the value of addressing unusual
side effects, but rare adverse drug reactions (ADRs) may be more relevant in certain
settings. Global information related to ADRs arises predominantly from western nations
(Ferner and Aronson, 2006). Cultural aspects related to genetic make-up, dietary patterns
and alternate available imported or manufactured brands, all influence local medication
safety advice and decision making (Wilbur, 2013). Recognizing otherwise obscure side
effects in patients could serve as important context-specific pharmacovigilance signal
detection if appropriately channeled (Isah et al., 2012; Vaidya et al., 2010; Swamy et al., 2015).
There is little about clinical reasoning (clinical decision making or clinical judgment)
found in the pharmacy literature (Gregory et al., 2016). Existing biomedical research
pertains to nurses, therapists and physicians, namely, distinguishing how novice and
experts arrive at initial diagnosis following patient history and physical examination
data gathering (through actual or simulated means) (Field, 2004; Jensen et al., 2000;
Ericsson, 2007; Daley, 1999). However, consistent with various clinical reasoning models,
our findings do not suggest discipline-distinct processes when determining patient-specific
risk communication decisions (Marcum, 2012). The way pharmacists prioritized specific
drug safety elements for patient counseling was often affected by prior experiences.
As previously determined in other professions, clinicians store and organize information
related to patient conditions in their memory as an illness script and can then draw upon
these models to inform care decisions (Charlin et al., 2007). As it pertains to medication
counseling, pharmacists would not use such exemplars for medical diagnostic purposes
per se, but instead to recognize patient dispositions. Verbal and non-verbal cues related to
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language, education, engagement and the individual’s affect may be discerned to guide
re-framing side effect information to optimize understanding, given previous counseling
outcomes with similar individuals. Such patient-tailored messaging is meaningful. Studying
patient preferences and the way they understand written and verbal medication safety
information shows that information is not uniformly interpreted and can have negative
implications on medication use (Tong et al., 2016; Berry et al., 1998). Unintentionally
provoking therapeutic non-adherence by adverse effect counseling is a well-documented
concern among health providers in the region (Wilbur et al., 2015; Silbernann and
Hassan, 2011; Al Qasem et al., 2011). As in some Asian, European and Latin countries,
non-disclosure is prevalent among Arab Middle Eastern cultures (Faria and Southami,
1997). Communication style for Arabic speakers may be indirect in that facts or ideas that
might prove distressing are not explicated (Feghali, 1997). Fear about medication side
effects has not been identified as a patient-related factor for non-adherence in the region (Al
Qasem et al., 2011). Indeed, patient studies in the Middle East indicate preference for such
information (Al-Saffar, et al., 2008).
Like other clinical reasoning applications, such as arriving at a diagnosis and choosing a
management plan, the risk communication strategy may be challenging to replicate in
undergraduate health professional curricula (Han et al., 2014; Thistlethwaite and Tie, 2007).
For pharmacy students, side effect mechanisms and prevalence may be covered in
pharmacology and therapeutics courses, respectively, and may even be noted in critical
appraisal exercises using evidence-based medicine. Meanwhile, communicating ADR
information may be practiced with peers or standardized patients in professional skills
courses (Mesquita et al., 2010). While experienced clinicians make decisions according to
deliberate analysis, concurrent complementary pattern recognition of illness scripts
is not necessarily a conscious process and therefore not easily taught (Ericsson, 2007).
Campus-based strategies to scaffold pre-existing knowledge, for use in patient-case solving,
include problem-based learning, self-explanations and schematically representing ideas
(concept maps) (Bowen, 2006). However, mastering theoretical or simulated medication and
patient safety content and communication does not guarantee translation into professional
competency within diverse care settings (Rudaz et al., 2013). Experiential learning remains
paramount for health professional students to build illness script databases enriched
with repeated exposure to patients over time and the deliberate practice of risk
communication guided by frequent feedback (Ericsson, 2008). Pharmacy students enrolled
in North-American accredited programs will complete up to 40 weeks in direct-patient care
settings before graduation (Accreditation Council of Pharmacy Education, 2016; Canadian
Council for Accreditation of Pharmacy Programs, 2014). Clinical supervisors can actively
translate clinical concepts into safe patient care through purposeful questioning,
by encouraging reading prototypical cases for comparison with encountered patients and
employing think-aloud techniques to further support connections between patient
encounters (Bowen, 2006; Lubarsky et al., 2015). Finally, our participants encouraged
student abilities consistent with clinical reasoning skills, namely, tolerance for ambiguous
situations that they will assuredly face in practice.
While our study is the first to explore how pharmacists make decisions about
communicating safety information during medication counseling, several limitations are
noted. Participants were sampled from healthcare providers specializing in cardiology.
We do not know how experts in other medical disciplines make decisions regarding
medication risk communication. However, studying nurses and pharmacists working locally
in oncology settings also identify that clinician assessment of the patient’s psychological
health as a consideration in side effect education (Wilbur et al., 2015). Our findings may also
be context specific to the Middle East. Qualitative studies are unlike quantitative inquiries,
in that generalizability is theoretical as opposed to statistical, but pharmacists providing
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medication counseling in cultural settings where patients expect that adverse effect
disclosure may use different approaches to prioritizing safety information. We used focus
group discussions to answer our research question, but ethnographic methods, such as
directly observing patient counseling encounters, could have yielded actual risk
communication dialogue that is different from what was described by pharmacists.
Similarly, we might have also observed our pharmacists supervising students to determine
what strategies they use to role model side effect counseling and the feedback given to
students interacting with patients.
Conclusions
Pharmacist decision making, when prioritizing medication risk communication, relied
heavily on prior patient encounters. Practical experience as a critical undergraduate health
professional patient safety instructional element is therefore underscored. Strategies for
how clinical supervisors can develop associated clinical reasoning should be formally
promoted in pharmacy programs.
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